I-IIIa期非小细胞肺癌临床分期的准确性:基于个体参与者数据的分析
该研究利用随机对照试验的个体参与者数据,评估I-IIIa期非小细胞肺癌临床TN分期与病理TN分期的一致性。在698例仅接受手术(±放疗)的患者中,48%的病例临床与病理分期不一致,34%被临床低估、14%被高估。临床分期在10%的病例中未能检出T4病变,并在38%的病例中错误分类淋巴结病变。
要点
- 临床与病理分期不一致率高达48%,其中34%被低估、14%被高估。
- 临床分期在10%的病例中未能检出T4病变。
- 淋巴结病变的临床分期错误分类率为38%。
核心结论
- 临床与病理分期一致性欠佳,T和N分期的差异可能分别导致10%和38%的病例治疗决策不同。
研究设计与样本
- 基于随机对照试验个体参与者数据的分析,纳入698例仅接受手术(±放疗)且具有临床和病理TNM分期数据的患者。
主要发现
- 48%的病例临床与病理分期不一致,34%被临床低估、14%被临床高估。
- 分期一致性未与年龄(P = .12)、性别(P = .62)、组织学(P = .82)、分期方法(P = .32)或随机化年份(P = .98)相关。
- 临床分期在10%的病例中未能检出T4病变,在38%的病例中错误分类淋巴结病变。
- 低估患者较差的生存可由潜在的病理TNM分期解释。
临床怎么用
- 临床分期与病理分期的差异可能影响治疗决策,需关注T4病变和淋巴结病变的准确评估。
局限性
- 分析仅基于仅接受手术(±放疗)的对照组患者,可能限制结论的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical staging of non-small cell lung cancer (NSCLC) helps determine the prognosis and treatment of patients; few data exist on the accuracy of clinical staging and the impact on treatment and survival of patients. We assessed whether participant or trial characteristics were associated with clinical staging accuracy as well as impact on survival. METHODS: We used individual participant data from randomized controlled trials (RCTs), supplied for a meta-analysis of preoperative chemotherapy (± radiotherapy) vs surgery alone (± radiotherapy) in NSCLC. We assessed agreement between clinical TNM (cTNM) stage at randomization and pathologic TNM (pTNM) stage, for participants in the control group. RESULTS: Results are based on 698 patients who received surgery alone (± radiotherapy) with data for cTNM and pTNM stage. Forty-six percent of cases were cTNM stage I, 23% were cTNM stage II, and 31% were cTNM stage IIIa. cTNM stage disagreed with pTNM stage in 48% of cases, with 34% clinically understaged and 14% clinically overstaged. Agreement was not associated with age (P = .12), sex (P = .62), histology (P = .82), staging method (P = .32), or year of randomization (P = .98). Poorer survival in understaged patients was explained by the underlying pTNM stage. Clinical staging failed to detect T4 disease in 10% of cases and misclassified nodal disease in 38%. CONCLUSIONS: This study demonstrates suboptimal agreement between clinical and pathologic staging. Discrepancies between clinical and pathologic T and N staging could have led to different treatment decisions in 10% and 38% of cases, respectively. There is therefore a need for further research into improving staging accuracy for patients with stage I-IIIa NSCLC.
引用
- Navani N, Fisher DJ, Tierney JF, et al. The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data. Chest. 2018. PMID: 30391190. doi:10.1016/j.chest.2018.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。